anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Ocular emergencies require immediate intervention to prevent rapid vision loss or functional impairment. The aim of this study was to determine the proportion of true ocular emergencies among patients who presented to the general emergency department with ocular complaints and were referred to the Eye Clinic.
METHODS: In a retrospective cross-sectional study in a tertiary hospital in Istanbul, patients aged 0-100 years who presented to the general emergency department with ocular complaints between January and December 2022 were included. Inconclusive diagnoses and incomplete records were excluded. Patients were divided into three groups: top eye emergencies (TE), relative eye emergencies (REE), and non-emergency eyes (NEE).
RESULTS: Among the 652,224 individuals seeking care, 9,982 (1.5%) were referred to the Eye Emergency Clinic. Of these, 2,788 (27.9%) were female, and 7,194 (72.1%) were male, with ages ranging from 0 to 98 years. TopEye Emergencies (TEE), Relative Eye Emergencies (REE), and Non-Eye Emergencies (NEE) accounted for 13%, 60%, and 27% of the cases, respectively. Common top-eye emergencies (TEE) include chemical injuries, orbital-preseptal cellulitis, and orbital fractures. Relative eye emergencies (REEs) commonly feature corneal foreign bodies, corneal erosion, and conjunctivitis. Nonemulsion eye (NEE) methods involve simple eye redness, trauma without eye involvement, and subconjunctival haemorrhage.
CONCLUSIONS: Consistent with the literature, 1.5% of patients presenting to the general emergency department had eye complaints.However, 27% of those referred to the ophthalmological clinic did not have an urgent eye condition. This is partly due to the high proportion of patients presenting to the emergency department with ocular complaints and the lack of knowledge of ophthalmological diseases by emergency physicians, leading to unnecessary referrals to the ophthalmology clinic, resulting in a loss of the workforce and reduced time allocated to patients with true ocular emergencies.
Patients with NSCLC who have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase. ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain. Patients received AUY922 at 70 mg/m\^2 weekly infusions.
PURPOSE: Roux-en-Y gastric bypass (RYGB) leads to the improvement of many obesity-associated conditions. The degree to which post-operative macronutrient composition contributes to metabolic improvement after RYGB is understudied.
METHODS: A mouse model of RYGB was used to examine the effects of diet on the post-operative outcomes of RYGB. Obese mice underwent either Sham or RYGB surgery and were administered either chow or HFD and then monitored for an additional 8 weeks.
RESULTS: After RYGB, reductions to body weight, fat mass, and lean mass were similar regardless of diet. RYGB and HFD were independently detrimental to bone mineral density and plasma vitamin D levels. Independent of surgery, HFD accelerated hematopoietic stem and progenitor cell proliferation and differentiation and exhibited greater myeloid lineage commitment. Independent of diet, systemic iron deficiency was present after RYGB. In both Sham and RYGB groups, HFD increased energy expenditure. RYGB increased fecal energy loss, and HFD after RYGB increased fecal lipid content. RYGB lowered fasting glucose and liver glycogen levels but HFD had an opposing effect. Indices of insulin sensitivity improved independent of diet. HFD impaired improvements to dyslipidemia, NAFLD, and fibrosis.
CONCLUSION: Post-operative diet plays a significant role in determining the degree to which RYGB reverses obesity-induced metabolic abnormalities such as hyperglycemia, dyslipidemia, and NAFLD. Diet composition may be targeted in order to assist in the treatment of post-RYGB bone mineral density loss and vitamin D deficiency as well as to reverse myeloid lineage commitment. HFD after RYGB continues to pose a significant multidimensional health risk.
The present invention proposes an efficient method to prognose the evolution of a solid cancer in a subject in need thereof, by analysing the frequency of a particular subset of dendritic cells as well as their relative number as compared to that of another subset of dendritic cells in a tumour sample of said subject. More precisely, the method of the invention comprises the step of detecting and quantifying the frequency of CD207 +  conventional dendritic cells of type 2 and 3 ("CD207 +  DC2+DC3") in a tumour sample of said subject. If the frequency of said cells is high, in particular in the tumour core, then it means that the subject has a bad prognosis. The method of the invention also comprises the calculation within the tumour of the ratio of the number of conventional dendritic cells of type 1 (cDC1) to the number of CD207 +  DC2+DC3 to predict T-cell clonality in the tumour. As a matter of fact, the inventors herein establish that the CD207 +  DC2+DC3 participate in the regulation of the anti-tumour T-cell cytotoxicity by limiting T-cell clonality and impairing the CD8 +  tissue resident memory T cell (TRM) response. Their analysis furthermore reveals that the CD207 +  DC2+DC3 are enriched in biopsies from later deceased patients as compared to alive patients suffering from different solid cancers. The inventors also propose to reduce the abundance of these cells within the tumour core, e.g., by appropriate drugs, in order to limit the development of said solid tumour in the subject.
The diagnosis and management of chronic nonspinal osteomyelitis can be challenging, and guidelines regarding the appropriateness of performing percutaneous image-guided biopsies to acquire bone samples for microbiological analysis remain limited. An expert panel convened by the Society of Academic Bone Radiologists developed and endorsed consensus statements on the various indications for percutaneous image-guided biopsies to standardize care and eliminate inconsistencies across institutions. The issued statements pertain to several commonly encountered clinical presentations of chronic osteomyelitis and were supported by a literature review. For most patients, MRI can help guide management and effectively rule out osteomyelitis when performed soon after presentation. Additionally, in the appropriate clinical setting, open wounds such as sinus tracts and ulcers, as well as joint fluid aspirates, can be used for microbiological culture to determine the causative microorganism. If MRI findings are positive, surgery is not needed, and alternative sites for microbiological culture are not available, then percutaneous image-guided biopsies can be performed. The expert panel recommends that antibiotics be avoided or discontinued for an optimal period of 2 weeks prior to a biopsy whenever possible. Patients with extensive necrotic decubitus ulcers or other surgical emergencies should not undergo percutaneous image-guided biopsies but rather should be admitted for surgical debridement and intraoperative cultures. Multidisciplinary discussion and approach are crucial to ensure optimal diagnosis and care of patients diagnosed with chronic osteomyelitis.
Systems, methods, and computer-readable media for managing healthcare environments are provided. In embodiments, a real-time status of a clinical device, along with a location, is received. The location of the clinical device is obtained via a clinical device identifier that is tracked by a plurality of sensors in a healthcare environment. A clinical device may be identified as inappropriate for use and an alert presented to a clinician including the problem of the clinical device and the location thereof. A replacement clinical device may be located, using clinical identifiers, and presented to the clinician. Such monitoring and location awareness facilitates efficient responses to healthcare situations.
Food protein-induced enterocolitis syndrome (FPIES) is a food allergy that results in repetitive vomiting, lethargy, and pallor within 1 to 4 hours of food ingestion. One of the issues in its management is the introduction of new foods. Over the past 25 years, suggestions have been made mainly based on the likelihood that a given food family could induce an episode of acute FPIES. Thus, foods have been categorized into low, moderate, and high risk. The suggestion was always to postpone the introduction of moderate- or high-risk foods, leaving the decision whether to introduce them at home or in hospital to the doctor. These suggestions were designed for all children with acute FPIES, regardless of their geographical area. However, it is true that these suggestions are the result of expert opinion. In recent years, studies have been published that have shown that the risk category of foods varies according to geographical area and so does the prevalence of single FPIES versus multiple FPIES. For this reason, we believe that the introduction of new foods in the child with acute FPIES can and should be tailored according to the geographical area.
The present invention provides a method for producing turmeric effective component. Turmeric material is ground and added with 70 to 95 percent of ethanol for extraction; the turmeric material is loaded on nonpolar macroporous adsorptive resin and ethanol/water is used for eluting; the eluent is collected, concentrated and dried to obtain turmeric macroporous resin component; then turmeric effective component is obtained through industrial production of chromatographic separation and mobile phase of methanol water. The main active ingredients are curcumin, demethoxycurcumin and bisdemethoxycurcumin and the total content is up to 97.3 percent. The turmeric effective component produced by the present invention gets rid of impurities and increases the content of the main active ingredients. In production, the present invention has high repeatability, good maneuverability, easy standardization and industrialization. At the same time, the present invention has certain directive significance for quality control of turmeric herb.
Participants with AC mCRPC in Cohort G will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
Administer according to the PK/PD optimized regimen with the goal of increasing T\>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
The invention belongs to the medicine and pharmaceutical field, and relates to applications of hydrogen sulfide and a donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders. Animal experiments slowly administrating NaHS are adopted. Results show that plasma cholesterol and blood pressure of GK diabetic rats and of Wistar rats can be lowered by slowly administrating the NaHS. The results show that the hydrogen sulfide and the donor thereof sodium hydrosulfide have a certain adjusting function for 2-type diabetes accompanied with the lipid metabolism disorders and that the hydrogen sulfide and the donor thereof sodium hydrosulfide can improve the abnormal liver function. The hydrogen sulfide and the donor thereof sodium hydrosulfide can improve the lipid metabolism disorders and fatty liver in the metabolic syndrome, reduce generation of liver injury, and can be used for preparation of medicines treating the lipid metabolism disorders. The hydrogen sulfide and the donor thereof sodium hydrosulfide can be used for preparation of medicines treating hyperlipoprotememia, hypertriglyceridemia, high cholesterol, fatty liver and adiposity, and medicines for preventing liver injury caused by the lipid metabolism disorders.
ABSTRACT OF THE DISCLOSURE           A provisional crown-and-bridge resin comprising a liquid resin component and a powder component.  The liquid resin component contains tetrahydrofurfuryl methacrylate as a major ingredient and is free from methyl methacrylate. It also contains an anti-oxidant and an accelerator.  The pow-der component contains poly (ethyl methacrylate) as a major ingredient and a curing agent for the resin component.  The powder is mixed with the resin shortly before application at a ratio of about two to about five parts of powder to one part of liquid resin by weight, to give a suitably flowing mixture.  The resin component may also contain ethyl metha-crylate as a major ingredient and may contain ethoxylated bisphenol A dimethacrylate as a major ingredient.  The pow-der may include a substantial proportion of amorphous silica and preferably incorporates a substantial amount of X-ray opaque barium glass.
Three (N = 3) subjects with treatment refractory opioid use disorder will receive bilateral DBS implants in the NAc using the Abbott Medical Infinity DBS system. The primary outcome of this study is to demonstrate the safety of bilateral NAc DBS in patients with treatment-refractory opioid use disorder. Secondary outcomes include time to relapse, remission of opioid use, and change in opioid craving scores. Other secondary outcomes will include the following: Hamilton Depression Scale (HDS), neurophysiological tests, body weight and biochemical markers of health and nutrition. If effective, DBS may reduce opioid use and opioid relapse in people with opioid use disorder who may continue to display relapse despite ongoing multidisciplinary standard of care. DBS brain electrode implantation and implantation of the IPGs and extension wires will be done in the operating room and will require the subject to be admitted post-operatively for an overnight stay. Two weeks after the DBS operation, subjects will undergo systematic testing each of the quadripolar contacts and formal programming. Subsequent parameter settings will be changed at routine outpatient visits based on clinical effects. Standard of care can consist of methadone or buprenorphine maintenance treatment provided by an addiction specialist.
Hepatorenal syndrome (HRS) is associated with a dismal prognosis in patients with cirrhosis, and therapeutic options are limited. Biomarkers to identify patients with poor response to therapy are urgently needed. This study aimed to evaluate the predictive value of serum levels of uromodulin (sUMOD) in patients with cirrhosis and HRS treated with terlipressin and albumin (T/A). In total, 156 patients [81 patients with HRS treated with T/A, 42 patients with cirrhosis without kidney injury, and 33 patients with cirrhosis with prerenal acute kidney injury (AKI)] were included. sUMOD levels were analyzed by ELISA. Patients with HRS were prospectively followed for the composite endpoint of hemodialysis-/liver transplantation-free survival (HD/LTx-free survival). Of the 81 patients with HRS, 40 had HRS type 1 and 41 type 2. In the cohort of patients with HRS treated with T/A, median sUMOD level was 100 ng/mL (IQR 64; 144). sUMOD differed significantly between patients with HRS compared with patients without AKI (P = 0.001) but not between patients with HRS and prerenal AKI (P = 0.9). In multivariable analyses, sUMOD levels in the lowest quartile were independently associated with a lower rate of complete response to T/A (OR 0.042, P = 0.008) and a higher risk for reaching the composite endpoint of HD/LTX-free survival (HR 2.706, P = 0.013) in patients with HRS type 2 treated with T/A. In contrast, sUMOD was not significantly associated with these outcomes in patients with HRS type 1. sUMOD may be a valuable biomarker for identifying patients with HRS type 2 treated with T/A to predict response and prognosis.NEW & NOTEWORTHY Biomarkers identifying patients with hepatorenal syndrome (HRS) and poor response to therapy are urgently needed. In this study, lower serum uromodulin (sUMOD) levels were associated with poorer response to therapy with terlipressin and albumin and consequently with poorer prognosis in patients with HRS type 2. In patients with HRS type 1, there was no association between sUMOD and poorer prognosis.
PCT No. PCT/US97/01661 Sec. 371 Date Aug. 7, 1998 Sec. 102(e) Date Aug. 7, 1998 PCT Filed Feb. 6, 1997 PCT Pub. No. WO97/29178 PCT Pub. Date Aug. 14, 1997Sheets capable of developing a positive electostatic charge are used for a variety of surface cleaning operations. Polyester fabric, non-woven and chemically bonded with an acrylic latex is used to dust surfaces, to clean clothes, furniture and carpets. A light solvent such as isopropanol can be used with the sheets to loosen gummy soils. In one mode, the sheets are used in a hot air clothes dryer to remove soils and detritus from garments. Processes for cleaning a variety of fabric and hard surfaces are conducted using the sheets.
COUMADIN is a narrow therapeutic range (index) drug, and its action may be affected by factors such as other drugs and dietary vitamin K. Therefore, anticoagulation must be carefully monitored during COUMADIN therapy. Determine the INR daily after the administration of the initial dose until INR results stabilize in the therapeutic range. After stabilization, maintain dosing within the therapeutic range by performing periodic INRs. The frequency of performing INR should be based on the clinical situation but generally acceptable intervals for INR determinations are 1 to 4 weeks. Perform additional INR tests when other warfarin products are interchanged with COUMADIN, as well as whenever other medications are initiated, discontinued, or taken irregularly. Heparin, a common concomitant drug, increases the INR [see Dosage and Administration (2.8) and Drug Interactions (7)].

Determinations of whole blood clotting and bleeding times are not effective measures for monitoring of COUMADIN therapy.
Background: Persistent external pancreatic fistulas post-acute pancreatitis are a relatively rare complication, in an era of endoscopic and minimally invasive treatment, which can present a high rate of morbidity. Although most of the cases require surgical treatment, the possibility of a minimally invasive approach is yet to be established. This article highlights a case in which persistent external pancreatic fistula (PEPF) was managed laparoscopically, indicating the key steps, as well as the postoperative follow-up. Case report: We present the case of a 55-year-old patient who developed acute gallstone pancreatitis, which was unsuccessfuly managed through endoscopic methods, and who underwent laparoscopic necrosectomy. Furthermore, the patient developed persistent external pancreatic fistula for which a laparoscopic Roux-en-Y fistulojejunostomy was performed with good postoperative recovery and follow-up. Conclusion: Despite the scarcity of the procedure, laparoscopic Roux-En-Y Fistulojejunostomy can be considered an effective choice in the cases of persistent external pancreatic fistulas by taking the right precautions and with adequate case selection.
One hundred thirty women with unexplained infertility participated in a prospective clinical study. Patients were assigned at random to one of two groups. The first group (n=65) served as the study group and was given clomiphene citrate 50 mg (Tecnovula®, Techno Pharmaceuticals, Egypt) orally twice daily from the second day of their cycle through the seventh day and sildenafil (Respatio®, Pharma right group, Egypt) 20 mg tablets from the end of menstruation through ovulation. The second group (n=65) served as a control and received a placebo tablet in addition to the standard treatment of clomiphene citrate 50 mg (Tecnovula®). A transvaginal ultrasound was performed on all of the patients to assess ovulation, follicle count, and pregnancy. Consequences, including miscarriage, ectopic pregnancy, and multiple pregnancies, were monitored.
PURPOSE: Platinum-based chemotherapy is a mainstay of treatment for many childhood cancers but is associated with acute nephrotoxicity and long-term ototoxicity. There is emerging evidence of long-term renal complications. This study aimed to assess the prevalence of chronic kidney disease (CKD) in children treated with platinum chemotherapy (cisplatin and carboplatin) and identify potential risk factors for the development of CKD.
METHODS: We conducted a retrospective review of children diagnosed with hepatoblastoma, osteosarcoma, neuroblastoma, or medulloblastoma who received platinum chemotherapy over a 16 year timeframe. Patients were excluded if they did not have at least 3 years follow up data, died within 3 years of platinum chemotherapy, or if they relapsed. Clinical data were collected at baseline (first dose), 1 year, and at most recent follow up.
RESULTS: Of 328 treated patients, 147 met the inclusion criteria and were followed for a mean of 8.1 years (range 3-15.7 years). The median age at first dose was 3.7 years (IQR 1.7-9.6 years). CKD ≥grade 2 was present in 53(36%) at last follow up and 15(10%) had tubular dysfunction. A history of acute kidney injury at any time during treatment was associated with CKD (OR 3.12 CI 1.07-9.12, p =0.04). On multivariable analysis older age at platinum therapy (OR 1.2, CI 1.1-1.4, p = 0.004) and a high aminoglycoside or vancomycin trough level (OR 4.3, CI 1.9-9.7, p < 0.001) were risk factors for CKD.
CONCLUSION: The high rate of CKD in children treated with platinum chemotherapy warrants long-term follow-up and screening for progressive disease.
A water-dispersible multi-vitamin composition is prepared by incorporating a fat-soluble vitamin and a water-soluble vitamin into a solvent comprising ethanol and a blending agent consisting of glycerine and/or lactic acid.  A solution of a water-soluble vitamin in the blending agent may be mixed with a solution of a fat-soluble vitamin in ethanol.  Alternatively, a fat-soluble vitamin may be added to a solution containing ethanol, the blending agent and a water-soluble vitamin; or a fat-soluble vitamin and then a water-soluble vitamin may be added to a mixture of ethanol and the blending agent.  Aqueous dispersions may be prepared by agitating the composition with an aqueous medium.  The fat-soluble vitamins may be vitamins A, D and/or E, or their concentrates prepared from fish oils, carotene concentrates or irradiated cholesterol, ergosterol or 7-dehydro cholesterol or oil solutions thereof.  It is preferred to use high fat-soluble vitamin concentrates from which the portion insoluble in methanol or ethanol at low temperature (-20 DEG C) has been removed.  The water-soluble vitamins may be the synthetic products or concentrates of the naturally-occurring vitamins.  The vitamin B complex may be derived from rice bran, rice polishings, or milk whey or may be added as thiamin hydrochloride, synthetic riboflavin, nicotinic acid amide, pantothenic acid or calcium pantothenate.  Likewise, vitamin C may be used as a natural concentrate or a synthetic product.  The compositions may be added to aqueous food products such as milk, coffee, tea, chocolate or fruit juices or to aqueous medicinal preparations.  Antioxidants such as those described in Specifications 550,983 and 553,328 may be added. The presence of vitamin E will stabilize vitamins A and C.  The pH of the composition should be maintained below 5, if necessary by the addition of citric, tartaric or like non-toxic organic acid.